FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Device Regs Amended to Correct Errors

Federal Register notice: FDA amends certain medical device regulations to update mailing addresses and docket numbers.

latest-news-card-1
Biologics

Sandoz sBLA for Citrate-free Hyrimoz

FDA approves a Sandoz supplemental BLA for citrate-free Hyrimoz (adalimumab-adaz) injection, a biosimilar version of Abbvies Humira.

latest-news-card-1
Human Drugs

ICH Approves Gene Therapy S12 Guidance

The International Council for Harmonization approves the S12 guidance on nonclinical biodistribution studies for gene therapy products.

latest-news-card-1
Human Drugs

Changes Suggested for Cancer Drug Dosing Guidance

The Friends of Cancer Research suggests possible additions to an FDA draft guidance on optimizing the dosage of oncologic drugs.

latest-news-card-1
Human Drugs

Significant CGMP Violations at Dunagin Pharmaceuticals

FDA warns Rogers, AR-based Dunagin Pharmaceuticals, which does business as Massco Dental, about CGMP violations in its manufacturing of finished drugs...

latest-news-card-1
Human Drugs

Multiple Violations at Contract Manufacturer

FDA warns Torrance, CA-based Cosmetic Science Laboratories about CGMP and other violations in its production of finished drugs as a contract manufactu...

latest-news-card-1

Turn Gene Therapy into Reality: Marks

CBER director Peter Marks tells a Muscular Dystrophy Association conference about ways FDA is addressing barriers to developing gene therapies for rar...

latest-news-card-1

CDERs Requests for Intarcia Hearing

CDER submits a petition outlining its requests if the FDA chief scientist decides to grant Intarcia a hearing on its NDA for drug/device combination I...

latest-news-card-1
Human Drugs

Karuna Mid-Year NDA Planned for Schizophrenia Drug

Karuna Therapeutics plans a mid-year NDA for schizophrenia drug KarXT (xanomeline-trospium) after reporting positive topline results from a recent Pha...

latest-news-card-1
Marketing

Drug Promotion Research Landscape Analyzed

FDA and RTI International researchers review empirical studies of prescription drug promotion in the last decade and suggest areas for further study.